Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

16.7%

3 terminated/withdrawn out of 18 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

50%

9 trials in Phase 3/4

Results Transparency

67%

10 of 15 completed trials have results

Key Signals

10 with results

Enrollment Performance

Analytics

Phase 2

7(41.2%)

Phase 3

6(35.3%)

Phase 4

3(17.6%)

Phase 1

1(5.9%)

17Total

Phase 2(7)

Phase 3(6)

Phase 4(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials

NCT01767129Phase 2Completed

Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

Role: lead

NCT01584440Phase 2Completed

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

Role: lead

NCT01324232Phase 2Completed

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Role: lead

NCT02534038Phase 2Terminated

Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition

Role: lead

NCT02477670Phase 2Completed

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

Role: lead

NCT01832350Phase 4Terminated

Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease

Role: collaborator

NCT02176018Phase 2Completed

Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine

Role: collaborator

NCT03381664Phase 1Completed

Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants

Role: lead

NCT02496039Phase 4Terminated

Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)

Role: lead

NCT02153502Phase 2Completed

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Role: lead

NCT00573443Phase 3Completed

Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS

Role: lead

NCT01667679Phase 3Completed

Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

Role: lead

NCT01799941Phase 4Completed

Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)

Role: lead

NCT00113620Phase 3Completed

Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy

Role: lead

NCT00050232Phase 3Completed

Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

Role: lead

NCT00021697Phase 3Completed

Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

Role: lead

NCT00056524Phase 3Completed

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

Role: lead

NCT01366027Completed

PRISM Registry: Pseudobulbar Affect Registry Series

Role: lead

All 18 trials loaded